# CONVERGENCE_CHECK_V12_01

Timestamp: 2026-06-05 14:41 CEST

## Session Objective

Resolve the remaining supported disagreement-matrix cells, prioritizing genetics
cells under the V12 multi-tool triangulation standard, then leave clean resume
state.

## Credential Status

`OPENGWAS_JWT` was not visible to this process despite the V12 prompt stating
that it was available. New OpenGWAS/LDSC/HDL and cross-trait colocalization
were therefore not run.

This is not silently upgraded away. V12 genetics cells are supported by
triangulation across existing project evidence and published genetics, but they
remain below robust coloc-grade until an environment with working OpenGWAS
access reruns the genetics layer.

## Cells Resolved This Session

### 006: UC Genetics Versus Treatment Response

Status: `intervention_derived`

Evidence ecosystems combined:

- published cross-disease LDSC genetics;
- OpenTargets shared genetic target overlap;
- QTL/L2G target-resolution evidence;
- UC colon myeloid cell-state transcriptomics;
- V7/V8 mucosal treatment-response evidence.

Resolution:

MS and UC share upstream immune genetic liability, but UC response-transfer
biology depends on downstream mucosal dynamic IFN/APC change. Shared genetic
risk does not validate baseline IFN/APC as a response stratifier.

### 007: Crohn IFN/APC Versus Genetics

Status: `biological`

Evidence ecosystems combined:

- published cross-disease LDSC genetics;
- OpenTargets shared target overlap;
- QTL/L2G and same-gene cell-state evidence;
- Crohn colon myeloid IFN/APC transcriptomics;
- IBD response/repair context.

Resolution:

Crohn converges with the MS-adjacent APC axis downstream at colon myeloid
IFN/APC state more strongly than it converges with MS at inherited genetic risk.

### 008: Crohn Genetics Versus Treatment Response

Status: `intervention_derived`

Resolution:

Crohn's intermediate MS genetic proximity does not block downstream mucosal
treatment-response convergence. The transferable concept is early
compartment-relevant inflammatory-state downshift, not shared inherited cause.

### 009: Crohn Genetics Versus Tissue Repair / Resolution

Status: `intervention_derived`

Resolution:

Crohn's downstream repair/response-monitoring proximity to MS is stronger than
its inherited-risk proximity, but the transfer is limited to inflammatory-state
resolution monitoring, not remyelination biology.

## Matrix State

- Total supported disagreement cells: `10`.
- Resolved/classified cells: `10`.
- Completion: `100%`.
- Unresolved cells: `0`.

## Synthesis

The V12 matrix supports a layer-specific transfer-validity rule:

UC is the stronger gut-disease comparator for MS inherited risk, while both UC
and Crohn support downstream mucosal IFN/APC response-monitoring analogies.
Genetic transfer and treatment-response biomarker transfer are therefore
different axes and should not be collapsed into disease-level similarity.

## Hostile Critique

Strongest vulnerability:

- The genetics cells did not receive new executable OpenGWAS/coloc evidence.
  They are supported, not robust.

Response:

- The limitation is explicit in every V12 report and in the synthesis.
- Matrix cells are resolved as V12 supported triangulation findings, not as
  robust shared-causal-variant findings.
- The next upgrade is specific: run OpenGWAS/HDL/LDSC and cross-trait coloc for
  the UC/Crohn shared targets once the credential is actually visible.

Second vulnerability:

- Treatment-response and tissue-repair evidence can overlap in IBD.

Response:

- The known UC treatment-response versus tissue-repair overlap remains an
  artifact/scope correction, not a biological disagreement.
- Crohn repair transfer is framed narrowly as response-monitoring / resolution
  analogy, not as an independent remyelination or tissue-repair mechanism.

## Next Session First Action

No unresolved supported matrix cells remain. The next session should either:

1. upgrade the genetics layer if `OPENGWAS_JWT` is truly visible, starting with
   UC/MS and Crohn/MS colocalization; or
2. extend the matrix into lower-grade/thin-axis cells while preserving the same
   artifact-control discipline.
